SMILe-ICM reduces acute graft-versus-host disease after allogeneic stem cell transplantation, European trials find

Results from two randomised controlled studies published 24 October 2026 report lower incidence of the complication for transplant recipients receiving the integrated care model.

Stands on 1 first-party reading of PubMed and ClinicalTrials.gov, not reporting.

Nurse helps patient with new transplant care model AI illustrationhow this picture was made

Two European randomised controlled implementation trials have found the SMILe-ICM integrated care model reduced cumulative incidence of acute graft-versus-host disease among adult allogeneic stem cell transplant recipients. The study was published 24 October 2026 in Annals of Hematology, and is indexed on PubMed.^[1] 152 participants were randomised 1:1 to either usual care or the intervention. SMILe-ICM is a multicomponent model combining eHealth with advanced practice nurse-led self-management support. Authors reported cumulative incidence of acute GvHD was 34.2% in the SMILe-ICM group. Funding for the work was provided by Universitätsklinikum Freiburg.

Proof1 source · 1 publisher · signed

What this stands on

"Evaluating the effectiveness of the eHealth-faciLitated SMILe-integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies." published in Annals of hematology as a randomized controlled trial (PubMed 42928398, doi 10.1007/s00277-026-07333-1). Sample: 152 as stated in the abstract. Results as the authors report them: Adult alloSCT recipients were randomized · PubMed and ClinicalTrials.gov, read by the New studies instrument · the fact recordUnited Statesofficial source

Read directly from PubMed and ClinicalTrials.gov, the public registries of published studies and registered trials, not from anyone's report of it.